NEW
YORK, Sept. 30, 2024 /PRNewswire/ -- Moore
Law, PLLC, a shareholder litigation law firm located on Wall
Street, is investigating potential claims against:
Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO)
- Shareholders should email Fletcher@fmoorelaw.com; please
contact only if shares acquired before September 13, 2022
The investigation concerns misrepresentations to investors as to
the true nature of the patient population that was being tested in
Akero's SYMMETRY study. Specifically, despite telling investors
that the study's patient population was limited to those with NASH
induced cirrhosis (a fact that was key for data integrity and the
likelihood of study success), for approximately 20% of those being
tested Akero had not confirmed that the patients had NASH and that
NASH had in fact caused their cirrhosis.
Akero shocked the market on October 10,
2023 when the company posted disappointing interim data from
its Phase 2b SYMMETRY trial for EFX.
Specifically, Akero stated that 22% (28mg) and 24% (50mg) of those
on EFX and 14% on placebo indicated at least one stage improvement
in fibrosis with no worsening of NASH at week 36, the trial's
primary endpoint, but that these changes were not statistically
significant. In addition, Akero added that 12 patients, including
11 in EFX groups, discontinued the trial due to drug-related
adverse events. On this news, Akero's stock price fell $30.39 per share, or 62.61%, to close at
$18.15 per share on October 10, 2023.
If you own Akero Therapeutics, Inc. ("Akero")
(NASDAQ:AKRO), please contact Fletcher Moore by email
at fletcher@fmoorelaw.com or (212) 709-8245.
ABOUT MOORE LAW PLLC
Moore Law is a NYC plaintiff litigation law firm for
investors. We hold officers and directors accountable for
breaches of fiduciary duty, fraud, insider trading,
wasteful spending, and other corporate malfeasance. There is
no cost to you. Our investor cases are contingency only.
Fletcher Moore, Esq.
Moore Law, PLLC
fletcher@fmoorelaw.com
www.fmoorelaw.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/investor-action-notice--moore-law-pllc-encourages-investors-in-akero-therapeutics-inc-to-contact-law-firm-302263299.html
SOURCE Moore Law PLLC